The role of perioperative immunotherapy with chemotherapy in muscle-invasive bladder cancer (MIBC)

被引：0
作者：
Hwang, Min Woo
Aragon-Ching, Jeanny B. [1 ,2 ]
机构：
[1] Inova Fairfax Hosp, Dept Internal Med, Fairfax, VA USA
[2] Inova Schar Canc Inst, GU Med Oncol, Fairfax, VA USA
来源：
CHINESE CLINICAL ONCOLOGY | 2024年 / 14卷 / 02期
关键词：
Neoadjuvant chemotherapy; immune checkpoint inhibitors; durvalumab; radical cystectomy; muscle invasive bladder cancer (MIBC); NEOADJUVANT CHEMOTHERAPY; PHASE-III;
D O I：
10.21037/cco-25-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 11 条
[1]   Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial [J].
Basile, Giuseppe ;
Bandini, Marco ;
Gibb, Ewan A. ;
Ross, Jeffrey S. ;
Raggi, Daniele ;
Marandino, Laura ;
de Padua, Tiago Costa ;
Crupi, Emanuele ;
Colombo, Renzo ;
Colecchia, Maurizio ;
Lucian, Roberta ;
Nocera, Luigi ;
Moschini, Marco ;
Briganti, Alberto ;
Montorsi, Francesco ;
Necchi, Andrea .
CLINICAL CANCER RESEARCH, 2022, 28 (23) :5107-5114
[2]   KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). [J].
Galsky, Matt D. ;
Necchi, Andrea ;
Shore, Neal D. ;
Plimack, Elizabeth R. ;
Jia, Calvin ;
Sbar, Eric ;
Moreno, Blanca Homet ;
Witjes, Johannes Alfred .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[3]   KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). [J].
Hoimes, Christopher J. ;
Bedke, Jens ;
Loriot, Yohann ;
Nishiyama, Hiroyuki ;
Fang, Xiao ;
Kataria, Ritesh S. ;
Moreno, Blanca Homet ;
Galsky, Matt D. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4]   Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors [J].
Jubber, Ibrahim ;
Ong, Sean ;
Bukavina, Laura ;
Black, Peter C. ;
Comperat, Eva ;
Kamat, Ashish M. ;
Kiemeney, Lambertus ;
Lawrentschuk, Nathan ;
Lerner, Seth P. ;
Meeks, Joshua J. ;
Moch, Holger ;
Necchi, Andrea ;
Panebianco, Valeria ;
Sridhar, Srikala S. ;
Znaor, Ariana ;
Catto, James W. F. ;
Cumberbatch, Marcus G. .
EUROPEAN UROLOGY, 2023, 84 (02) :176-190
[5]   Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer [J].
Powles, Thomas ;
Catto, James W. F. ;
Galsky, Matthew D. ;
Al-Ahmadie, Hikmat ;
Meeks, Joshua J. ;
Nishiyama, Hiroyuki ;
Vu, Toan Quang ;
Antonuzzo, Lorenzo ;
Wiechno, Pawel ;
Atduev, Vagif ;
Kann, Ariel G. ;
Kim, Tae-Hwan ;
Suarez, Cristina ;
Chang, Chao-Hsiang ;
Roghmann, Florian ;
Ozguroglu, Mustafa ;
Eigl, Bernhard J. ;
Oliveira, Niara ;
Buchler, Tomas ;
Gadot, Moran ;
Zakharia, Yousef ;
Armstrong, Jon ;
Gupta, Ashok ;
Hois, Stephan ;
van der Heijden, Michiel S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (19) :1773-1786
[6]   A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) or D plus EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). [J].
Powles, Thomas ;
Drakaki, Alexandra ;
Teoh, Jeremy Yuen-Chun ;
Grande, Enrique ;
Fontes-Sousa, Mario ;
Porta, Camillo ;
Wu, Esther ;
Goluboff, Erik T. ;
Ho, Svetlana ;
Hois, Stephan ;
Gupta, Ashok Kumar ;
Catto, James W. F. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[7]   Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial [J].
Powles, Thomas ;
van der Heijden, Michiel S. ;
Castellano, Daniel ;
Galsky, Matthew D. ;
Loriot, Yohann ;
Petrylak, Daniel P. ;
Ogawa, Osamu ;
Park, Se Noon ;
Lee, Jae-Lyun ;
De Giorgi, Ugo ;
Bogemann, Martin ;
Bamias, Aristotelis ;
Eigl, Bernhard J. ;
Gurney, Howard ;
Mukherjee, Som D. ;
Fradet, Yves ;
Skoneczna, Iwona ;
Tsiatas, Marinos ;
Novikov, Andrey ;
Suarez, Cristina ;
Fay, Andre P. ;
Duran, Ignacio ;
Necchi, Andrea ;
Wildsmith, Sophie ;
He, Philip ;
Angra, Natasha ;
Gupta, Ashok K. ;
Levin, Wendy ;
Bellmunt, Joaquim .
LANCET ONCOLOGY, 2020, 21 (12) :1574-1588
[8]   Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study [J].
Powles, Thomas ;
O'Donnell, Peter H. ;
Massard, Christophe ;
Arkenau, Hendrik-Tobias ;
Friedlander, TerenceW. ;
Hoimes, Christopher J. ;
Lee, Jae Lyun ;
Ong, Michael ;
Sridhar, Srikala S. ;
Vogelzang, Nicholas J. ;
Fishman, Mayer N. ;
Zhang, Jingsong ;
Srinivas, Sandy ;
Parikh, Jigar ;
Antal, Joyce ;
Jin, Xiaoping ;
Gupta, Ashok K. ;
Ben, Yong ;
Hahn, Noah M. .
JAMA ONCOLOGY, 2017, 3 (09)
[9]  
Siefker-Radtke AO, 2019, ANN ONCOL, V30, P401
[10]   ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer [J].
Sonpavde, Guru ;
Necchi, Andrea ;
Gupta, Shilpa ;
Steinberg, Gary D. ;
Gschwend, Juergen E. ;
Van Der Heijden, Michiel Simon ;
Garzon, Nathalie ;
Ibrahim, Mohammed ;
Raybold, Bradley ;
Liaw, Danny ;
Rutstein, Mark ;
Galsky, Matt D. .
FUTURE ONCOLOGY, 2020, 16 (02) :4359-4368
12